A relatively new drug is boosting survival rates for women with a specific type of advanced breast cancer who haven’t responded to other treatments, according to a pair of clinical trials. The targeted antibody drug — trastuzumab deruxtecan (T-DXd, sold under the brand name Enhertu) — dramatically outperformed an older antibody drug in one trial,… read on > read on >



















